News
Miravo Healthcare announces receipt of Health Canada Notice of Compliance for the pediatric use of Blexten.
Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, announced Health Canada has issued a Notice of Compliance (NOC) in relation to the Company’s Supplement to New Drug Submission for the pediatric use of Blexten.
The pediatric use includes the approval of two new dosage formats; a 2.5mg/mL oral solution and a 10mg Quick Melt tablet. Upon commercial launch, which is anticipated for Q1 2022, the pediatric formats will be available to patients with a prescription from their healthcare provider.
Condition: Allergic Rhinitis
Type: drug